Mesa Laboratories (MLAB) risk factors, FY2025 10-K

Mesa Laboratories's FY2025 10-K, filed May 28, 2025, lists 48 risk factors in 4 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
484 groups
Section length
11k wordsItem 1A

Mesa Laboratories's biggest risks in the FY2025 10-K

  • Mesa Laboratories faces intense market competition, strict FDA and international regulatory requirements, and integration risks from strategic business acquisitions.
  • Significant revenue concentration relies on key customers, distributors, and specific product lines like Dialyguard.

The risks most specific to Mesa Laboratories

  • Operational Risks

    A significant disruption in, or breach in security of, our information technology systems or data could adversely affect our business, reputation and financial statements

    A security breach or disruption in our information technology systems could adversely affect our business, reputation, and financial statements.

  • Operational Risks

    Our financial results are subject to fluctuations in the cost and availability of components and commodities that we use in our operations

    Fluctuations in the cost and availability of raw materials and commodities, including metallic-based components, chemicals, and plastics, impact our manufacturing operations.

  • Operational Risks

    Changes to dialysis methods and equipment capabilities may decrease demand for our renal care products and negatively impact our financial statements

    Changes to dialysis methods and equipment capabilities may decrease demand for our Dialyguard product line, which accounts for one-third of our Calibration Solutions revenues.

  • Operational Risks

    Any inability to consummate acquisitions at our historical rate and at appropriate prices could negatively impact our growth rate and stock price

    Any inability to consummate acquisitions at our historical rate and appropriate prices could negatively impact our growth rate and stock price.

  • Legal, Regulatory, Compliance, and Reputational Risks

    Off-label marketing of our products could result in substantial penalties

    Off-label marketing of our products could result in substantial penalties from the FDA.

  • Legal, Regulatory, Compliance, and Reputational Risks

    Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products

    Certain product modifications may require new 510(k) clearances or force us to recall or cease marketing our products.

  • Financial and Tax Risks

    We may be required to recognize impairment losses for our goodwill and other intangible assets

    We may be required to recognize impairment losses for our $278.6 million in net carrying value of goodwill and other intangible assets.

  • Financial and Tax Risks

    The loss of key customers, or reductions in their demand for our products and services, could have a significant negative impact on our revenues, results of operations, and financial position

    The loss of key customers comprising greater than 10% of segment revenues could significantly impact our results.

All 48 risk factors

Headings as the filing states them, in filing order.

Business and Strategic Risks

  1. 01Conditions in the global economy, the markets we serve, and financial markets may adversely affect our business, financial statements, and access to capital markets
  2. 02adversely impacting market sizes and growth rates
  3. 03Our international operations subject us to a wide range of risks
  4. 04greater uncertainty, risk, expense and delay in commercializing products in certain foreign jurisdictions, including with respect to product and other regulatory approvals
  5. 05Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience volatility
  6. 06The markets for our current and potential products are competitive. Because of the range of products and services we sell and the variety of markets we serve, we encounter a wide variety of competitors, including several that possess both larger sales forces and greater capital resources
  7. 07Changing industry trends may affect our results of operations
  8. 08Our growth depends in part on the timely development, commercialization, and customer acceptance of new and enhanced products and services based on technological innovation
  9. 09If we are unable to continue to hire and retain skilled personnel, we will have difficulty manufacturing and marketing our products
  10. 10Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, distributors and other channel partners could adversely affect our financial statements

Operational Risks

  1. 11Significant developments or uncertainties related to social, political, regulatory and economic matters within the U.S. and internationally, including with respect to international trade policies and tariffs, could have an adverse effect on our business
  2. 12Geopolitical and macroeconomic pressures in the markets in which we operate may adversely affect our financial results
  3. 13A significant disruption in, or breach in security of, our information technology systems or data could adversely affect our business, reputation and financial statements
  4. 14Supply chain and manufacturing risks could adversely affect our financial results. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services could cause production interruptions, delays and inefficiencies
  5. 15Our financial results are subject to fluctuations in the cost and availability of components and commodities that we use in our operations
  6. 16Violation of data privacy laws could adversely affect our business, reputation and financial statements
  7. 17Changes to dialysis methods and equipment capabilities may decrease demand for our renal care products and negatively impact our financial statements
  8. 18We may be unable to efficiently manage our growth as a larger and more geographically diverse organization
  9. 19If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to a catastrophic event, our operations could be seriously harmed
  10. 20The life sciences and healthcare industries and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce costs, which could adversely affect our financial results
  11. 21The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our reputation, business and financial results could suffer
  12. 22Climate change, or legal or regulatory measures to address climate change and sustainability, may negatively affect us, and any actions we take or fail to take in response to such matters could damage our reputation
  13. 23Any inability to consummate acquisitions at our historical rate and at appropriate prices could negatively impact our growth rate and stock price
  14. 24Our acquisitions of businesses expose us to risks that could negatively impact our financial results
  15. 25The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities, or we may have acquisition agreements with no indemnification protection at all
  16. 26Future strategic transactions or acquisitions may require us to seek additional financing, which we may not be able to secure on favorable terms, or at all

Legal, Regulatory, Compliance, and Reputational Risks

  1. 27Changes in governmental regulations may reduce demand for our products or services or increase our expenses
  2. 28We are subject to lawsuits and regulatory proceedings
  3. 29Our reputation, ability to do business and prepare financial statements may be impaired by improper conduct by any of our employees, agents or business partners
  4. 30We are subject to extensive regulation
  5. 31Off-label marketing of our products could result in substantial penalties
  6. 32Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products
  7. 33Potential product liability suits against us, product defects or unanticipated use or inadequate disclosure with respect to our products or services could adversely affect our business, reputation and our financial statements
  8. 34We are subject to export and import control laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate such laws and regulations
  9. 35We are subject to laws and regulations governing government contracts

Financial and Tax Risks

  1. 36Foreign currency exchange rates may adversely affect our financial statements
  2. 37We may be required to recognize impairment losses for our goodwill and other intangible assets
  3. 38The loss of key customers, or reductions in their demand for our products and services, could have a significant negative impact on our revenues, results of operations, and financial position
  4. 39Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could affect our reported financial results
  5. 40negative impact on the trading price of our common stock
  6. 41Our failure to maintain appropriate corporate responsibility practices and disclosures could result in reputational harm, a loss of customer and investor confidence, and adverse business and financial results
  7. 42Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods
  8. 43Changes in tax law relating to multinational corporations could adversely affect our tax position
  9. 44Our business is subject to sales tax in numerous states
  10. 45The cost and availability of credit are subject to changes in the global economic environment. If conditions in major credit markets deteriorate, our ability to obtain debt financing or the terms associated with that debt financing may be negatively affected, which could affect our results of operations
  11. 46Additional stock issuances could result in significant dilution to our stockholders
  12. 47Our stock price may be volatile, which may subject us to a securities class action litigation or could cause shareholders to lose part or all of their investment
  13. 48our results of operations and financial performance

Other Mesa Laboratories 10-Ks

  • FY2026 10-K risk factors
    49 risks12 new11 dropped37 reworded

    New risks focus on supply-chain disruption, tariffs, FDA and cybersecurity compliance, and the March 2026 CEO transition.

    Filed Jun 03, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.